Myocardial Infarction News and Research

RSS

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the first quarter of 2010. Management is working diligently to finalize the amended Annual Report on Form 10-K for 2009.

18 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Ambulance fees will deter emergency calls for help and risks lives: Study

Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.

14 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

This week, TCA Cellular Therapy's Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific conference in San Diego.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

Swedish researchers present a new principle for inhibiting atherosclerosis

7 May 2010

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals.

6 May 2010

Non-compliance, NSAIDs use inhibit clinical benefit of aspirin

Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science at Florida Atlantic University, was the first to demonstrate that aspirin prevents a first heart attack based on his landmark Physicians Health Study (PHS).

5 May 2010

Medtronic completes enrollment in first of two CURE-AF clinical trials

Medtronic, Inc., today announced completion of patient enrollment in the first of two studies in the company's CURE-AF (Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation) clinical trial.

4 May 2010

Left ventricular mass may help predict future cardiovascular and renal outcomes: Study

Data presented today at the American Society of Hypertension, Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) indicate that in men with high cardiovascular risk, left ventricular mass may help better predict future cardiovascular and renal outcomes, including hemodialysis.

3 May 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

Merck disappointed with Supreme Court affirming lower court's ruling in federal securities class action suit

Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.

28 Apr 2010

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.

20 Apr 2010

Research roundup: Revamping NCI Clinical Trials, reducing malpractice suits, health disparities persist

A National Cancer Clinical Trials System For The 21st Century: Reinvigorating The NCI Cooperative Group Program - The "system for conducting cancer clinical trials in the United States is approaching a state of crisis," according to this report on inefficiencies and funding issues faced by the NCI's Clinical Trials Cooperative Group Program - which comprises 10 groups, more than 3,100 institutions, 14,000 investigators and more than 25,000 patients in clinical trials each year.

17 Apr 2010

Myocardial Infarction News and Research

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

Athersys presents data supporting MultiStem programs

Ambulance fees will deter emergency calls for help and risks lives: Study

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

CHD mortality rate in Ontario decreased by 35%: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

Natazia tablets receive FDA approval for prevention of pregnancy

Swedish researchers present a new principle for inhibiting atherosclerosis

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

Non-compliance, NSAIDs use inhibit clinical benefit of aspirin

Medtronic completes enrollment in first of two CURE-AF clinical trials

Left ventricular mass may help predict future cardiovascular and renal outcomes: Study

Celera reports net loss of $12.5M for first-quarter 2010

Merck disappointed with Supreme Court affirming lower court's ruling in federal securities class action suit

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Research roundup: Revamping NCI Clinical Trials, reducing malpractice suits, health disparities persist

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News